Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Cytek Biosciences, Inc.NASDAQ: CTKB
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin holds steady near 48.2%
Gross margin was 48.2% in Q1 FY2026, down 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 51.7%, down 3.2 pp year over year. Over 3 fiscal years it narrowed by 9.7 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 51.8%
- Year-over-year change
- -3.6pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.8% | -3.6pp |
| FY2024 | 2024-12-31 | 55.4% | -1.3pp |
| FY2023 | 2023-12-31 | 56.7% | -4.9pp |
| FY2022 | 2022-12-31 | 61.6% | -0.3pp |
| FY2021 | 2021-12-31 | 61.9% | — |
Gross Margin vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's LTM Mar 2026 gross margin of 51.7% is the 4th highest of the 6 companies compared; the peer median is 51.9%.
- Its year-over-year change of -3.2 pp is the lowest of 6, against a peer median of -0.9 pp.
- Over three fiscal years its change of -9.7 pp compares with a peer median of -3.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 71.9% | +3.0 pp | -7.6 pp | |
| LTM Jul 2026 | 53.7% | +0.8 pp | -1.9 pp | |
| LTM Jun 2026 | 51.9% | -0.9 pp | -3.9 pp | |
| LTM Mar 2026 | 51.7% | -3.2 pp | -9.7 pp | |
| LTM Mar 2026 | 48.3% | -1.2 pp | +12.0 pp | |
| LTM Jun 2026 | 46.7% | -1.6 pp | -5.7 pp | |
| Peer median (excluding CTKB) | 51.9% | -0.9 pp | -3.9 pp | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 127.95M | 164.04M | 193.02M | 200.45M | 201.49M |
| Cost of Revenue | 48.81M | 63.06M | 83.59M | 89.35M | 97.03M |
| Gross Profit | 79.14M | 100.97M | 109.43M | 111.11M | 104.46M |
| Gross Margin | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| Research & Development | 24.44M | 34.86M | 44.15M | 39.4M | 36.47M |
| Selling, General & Admin | 45.55M | 67.92M | 93.12M | 92.23M | 108.38M |
| Operating Expenses | 69.99M | 102.78M | 137.27M | 131.63M | 144.84M |
| Depreciation & Amortization | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| EBITDA | 8.92M | 9.49M | (4.41M) | 4.79M | (17.39M) |
| EBITDA Margin | 7.0% | 5.8% | -2.3% | 2.4% | -8.6% |
| Operating Income | 9.16M | (1.8M) | (27.85M) | (20.52M) | (40.38M) |
| Operating Margin | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| Interest Income | 49K | 4.62M | 6.41M | 10.36M | 2.22M |
| Interest Expense | 1.74M | 2.57M | 2.07M | 0 | 474K |
| Other Income / Expenses | (3.22M) | 3.06M | 12.14M | 14.82M | 10.54M |
| Income Before Tax | 5.94M | 1.26M | (15.71M) | (5.7M) | (29.84M) |
| Pre-Tax Margin | 4.6% | 0.8% | -8.1% | -2.8% | -14.8% |
| Income Tax Expense | 2.91M | (1.22M) | (3.56M) | 320K | 36.7M |
| Net Income | 3M | 2.58M | (12.15M) | (6.02M) | (66.54M) |
| Net Margin | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% |
| EPS (Basic) | 0.03 | 0.02 | (0.09) | (0.05) | (0.52) |
| EPS (Diluted) | 0.03 | 0.02 | (0.09) | (0.05) | (0.52) |
| Weighted Avg Shares | 133.75M | 134.51M | 135.28M | 130.61M | 127.75M |
| Weighted Avg Shares (Diluted) | 133.75M | 138.56M | 135.28M | 130.61M | 127.75M |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.